4 completed, 1 withdrawn. 2 Not applicable, 1 Phase 1, 1 Phase 2, 1 Phase 4.
| Phase | Trials | Status |
|---|---|---|
| Not applicable | 2 | Completed 2 |
| Phase 1 | 1 | Completed 1 |
| Phase 2 | 1 | Withdrawn 1 |
| Phase 4 | 1 | Completed 1 |
Follow saline IV: new trials by email Literature Review of saline IV trials Research Report on saline IV
Tick up to 5 trials to compare them side by side (eligibility, arms, endpoints, adverse events) in a Literature Matrix.
| Trial | Phase | Status | Sponsor | Enrollment | Start | Updated |
|---|---|---|---|---|---|---|
| Lidocaine Infusion With ERAS Protocol for Pancreatic Cancer Surgery: Effect on Pain and Patient Immunity. Lidocaine IV, saline IV - ERAS, Lidocaine | Not applicable | Completed | Alexandria University | 30 | 2022-04-20 | 2024-08-21 |
| Anakinra, COVID-19, Cytokine Storm Anakinra, 0.9% Saline - Covid19, Cytokine Storm | Phase 2 | Withdrawn | Weill Medical College of Cornell University | 2021-12-01 | 2022-01-25 | |
| Systemic Lidocaine Versus Ultrasound-guided Adductor Canal Block for Patients Undergoing Total Knee Arthroplasty Lidocaine IV, Saline IV - Arthroplasty, Replacement, Knee, Total Knee Arthroplasty | Phase 4 | Completed | Rhode Island Hospital | 120 | 2021-03-01 | 2026-06-15 |
| Effect of Lidocaine Plus Dexmedetomidine Infusion on PONV lidocaine and dexmedetomidine IV, saline IV - Lidocaine, Dexmedetomidine | Not applicable | Completed | Xu Siqi | 60 | 2018-01-01 | 2019-01-08 |
| A Study of Metyrapone and Oxazepam Combination Product (EMB-001) and Cocaine EMB-001, Placebo, Cocaine IV - Cocaine Use Disorder | Phase 1 | Completed | Embera NeuroTherapeutics, Inc. | 18 | 2016-07-01 | 2017-08-01 |
COVID-19 (1) · Cytokine Release Syndrome (1) · Pancreatic Neoplasms (1) · Postoperative Nausea and Vomiting (1)
Alexandria University (1) · Embera NeuroTherapeutics, Inc. (1) · Rhode Island Hospital (1) · Weill Medical College of Cornell University (1) · Xu Siqi (1)
United States (3) · China (1) · Egypt (1)
Debra Kelsh, MD (1) · Iris Y Navarro-Millan, MD, MSPH (1) · Vendhan Ramanujam, M.D. (1)
U01DA038879 (1)